Ultragenyx Pharmaceutical (RARE)
Develops and commercializes therapies for serious rare and ultra-rare genetic diseases.
$15.58
After hours−0.03 (−0.19%)
At close$15.61(+6.55%)
Something off on this page? Send us feedback.
Next report
Nov 3, 26
in 42 days
EPS estimate
−$0.65
Revenue estimate
$183.2M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$1.39−$1.57−$1.17−$1.81−$1.29−$1.84−$0.90Pending
Estimate−$1.32−$1.54−$1.27−$1.23−$1.20−$1.49−$1.22−$0.65
Surprise−5.3%−1.9%+7.9%−47.2%−7.5%−23.7%+26.2%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$164.9M$139.3M$166.5M$159.9M$207.0M$136.0M$214.0MPending
Estimate$158.7M$162.4M$165.9M$199.8M$198.6M$158.2M$183.1M$183.2M
Surprise+3.9%−14.2%+0.3%−19.9%+4.2%−14.0%+16.9%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $0.49 | — | — |
| Sep 2027 | −$0.06 | — | — |
| Jun 2027 | −$0.26 | — | — |
| Mar 2027 | −$0.76 | — | — |
| Dec 2026 | −$0.25 | — | — |
| Nov 2026 | −$0.65 | — | — |
| Aug 2026 | −$1.22 | −$0.90 | +26.2% |
| May 2026 | −$1.49 | −$1.84 | −23.7% |
| Feb 2026 | −$1.20 | −$1.29 | −7.5% |
| Nov 2025 | −$1.23 | −$1.81 | −47.2% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Jul 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Jul 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $0.49 | — | — | $323.4M | — | — | — |
| Sep 2027 | −$0.06 | — | — | $263.7M | — | — | — |
| Jun 2027 | −$0.26 | — | — | $250.3M | — | — | — |
| Mar 2027 | −$0.76 | — | — | $196.9M | — | — | — |
| Dec 2026 | −$0.25 | — | — | $223.0M | — | — | — |
| Nov 3, 2026 | −$0.65 | — | — | $183.2M | — | — | — |
| Aug 4, 2026 | −$1.22 | −$0.90 | +26.2% | $183.1M | $214.0M | +16.9% | −3.4% |
| May 5, 2026 | −$1.49 | −$1.84 | −23.7% | $158.2M | $136.0M | −14.0% | +3.7% |
| Feb 12, 2026 | −$1.20 | −$1.29 | −7.5% | $198.6M | $207.0M | +4.2% | −12.7% |
| Nov 4, 2025 | −$1.23 | −$1.81 | −47.2% | $199.8M | $159.9M | −19.9% | −1.8% |
| Aug 5, 2025 | |||||||
| May 6, 2025 | |||||||
| Feb 13, 2025 | |||||||
| Nov 5, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 15, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Feb 16, 2023 | |||||||
| Nov 2, 2022 | |||||||
| Jul 28, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 10, 2022 | |||||||
| Nov 2, 2021 | |||||||
| Aug 2, 2021 | |||||||
| May 4, 2021 | |||||||
| Feb 11, 2021 | |||||||
| Oct 27, 2020 | |||||||
| Jul 30, 2020 | |||||||
| May 6, 2020 | |||||||
| Feb 13, 2020 | |||||||
| Nov 5, 2019 | |||||||
| Aug 1, 2019 | |||||||
| May 6, 2019 | |||||||
| Feb 19, 2019 | |||||||
| Nov 5, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 7, 2018 | |||||||
| Feb 20, 2018 | |||||||
| Nov 2, 2017 | |||||||
| Jul 27, 2017 | |||||||
| May 4, 2017 | |||||||
| Feb 16, 2017 | |||||||
| Nov 7, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 9, 2016 | |||||||
| Feb 25, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 13, 2015 |